Blood Establishment Registration and Product Lising Form FDA 2830

ICR 201201-0910-002

OMB: 0910-0052

Federal Form Document

Forms and Documents
Document
Name
Status
Form and Instruction
Modified
Form and Instruction
New
Form and Instruction
New
Supporting Statement A
2011-11-21
IC Document Collections
ICR Details
0910-0052 201201-0910-002
Historical Active 200812-0910-003
HHS/FDA
Blood Establishment Registration and Product Lising Form FDA 2830
Extension without change of a currently approved collection   No
Regular
Approved without change 03/08/2012
Retrieve Notice of Action (NOA) 01/04/2012
  Inventory as of this Action Requested Previously Approved
03/31/2015 36 Months From Approved 03/31/2012
2,818 0 2,621
1,389 0 1,467
0 0 0

Under section 510 of the Federal Food, Drug, and Cosmetic Act (the Act) (21 U.S.C. 360), any person owning or operating an establishment that manufactures, prepares, propagates, compounds, or processes a drug or device must register with the Secretary of Health and Human Services, on or before December 31 of each year, his or her name, place of business, and all such establishments must submit, among other information, a listing of all drug or device products manufactured, prepared, propagated, compounded, or processed by him or her for commercial distribution. The regulations of establishment registration and product listing for blood establishments are found in 21 CFR Part 607. These establishments are required to submit this information on Form FDA 2830.

US Code: 21 USC 360 Name of Law: FFDCA
  
None

Not associated with rulemaking

  76 FR 48167 08/08/2011
76 FR 79691 12/22/2011
No

  Total Approved Previously Approved Change Due to New Statute Change Due to Agency Discretion Change Due to Adjustment in Estimate Change Due to Potential Violation of the PRA
Annual Number of Responses 2,818 2,621 0 0 197 0
Annual Time Burden (Hours) 1,389 1,467 0 0 -78 0
Annual Cost Burden (Dollars) 0 0 0 0 0 0
No
No
The current decrease to 1,389 hours (-78 hours) is mostly attributed to a decrease in the number of initial registrations of blood product establishments (foreign and domestic). The increase in the number of responses is a result of a technical change in how this collection is organized in the system -- i.e., FDA separated one IC into three for clarity.

$105,885
No
No
No
No
No
Uncollected
ILa Mizrachi 301 796-7726 ila.mizrachi@fda.hhs.gov

  No

On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
 
 
 
 
 
 
 
    (i) Why the information is being collected;
    (ii) Use of information;
    (iii) Burden estimate;
    (iv) Nature of response (voluntary, required for a benefit, or mandatory);
    (v) Nature and extent of confidentiality; and
    (vi) Need to display currently valid OMB control number;
 
 
 
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.
01/04/2012


© 2024 OMB.report | Privacy Policy